Last updated: September 24, 2026
Cabotegravir sodium is the active pharmaceutical ingredient used in ViiV Healthcare’s oral and injectable cabotegravir products. Its commercial value is concentrated in two long-acting HIV products: Cabenuva, for treatment of HIV-1 infection with rilpivirine, and Apretude, for pre-exposure prophylaxis. The products have shifted cabotegravir from a conventional integrase inhibitor into a long-acting delivery platform with higher switching costs, specialized administration requirements, and greater manufacturing complexity.
ViiV does not separately report revenue for cabotegravir sodium. It reports product-level sales for Cabenuva and Apretude within its HIV portfolio. The financial trajectory has been positive, led by Cabenuva adoption in the United States and the expansion of injectable HIV prevention.
What is cabotegravir sodium and which products contain it?
Cabotegravir is an HIV-1 integrase strand-transfer inhibitor. Oral tablets contain cabotegravir sodium, while long-acting injectable products contain cabotegravir in an injectable nanosuspension formulation.
| Product |
Active ingredients |
Indication |
Approval |
| Vocabria tablets |
Cabotegravir sodium |
Oral lead-in or oral bridging therapy with rilpivirine |
FDA, January 2021 |
| Cabenuva injection |
Cabotegravir plus rilpivirine |
Complete regimen for virologically suppressed adults and adolescents with HIV-1 |
FDA, January 2021 |
| Apretude injection |
Cabotegravir |
HIV pre-exposure prophylaxis in adults and adolescents at risk of sexually acquired HIV |
FDA, December 2021 |
Cabenuva is administered monthly or every two months after an initiation regimen. Apretude is administered every two months after two initiation injections one month apart. The extended dosing interval is the central commercial differentiator against daily oral therapy.
The FDA labels identify cabotegravir sodium for the oral product and cabotegravir for the injectable products. The commercial market is therefore commonly described as the cabotegravir market, although the oral pharmaceutical form is cabotegravir sodium.[1-3]
How large is the cabotegravir market?
The addressable market includes HIV treatment, HIV prevention, and future long-acting infectious-disease applications. HIV treatment is the larger near-term opportunity because Cabenuva has an established reimbursement pathway and an existing population of patients receiving antiretroviral therapy.
The principal market segments are:
- Virologically suppressed patients switching from daily oral treatment to Cabenuva.
- Patients with adherence difficulties who may benefit from supervised dosing.
- Individuals seeking long-acting HIV prevention with Apretude.
- Public-health programs seeking alternatives to daily oral PrEP.
- International markets where injectable HIV treatment and prevention are being introduced through licensing and access agreements.
Cabenuva competes primarily with daily oral two-drug and three-drug regimens, including Biktarvy, Dovato, Triumeq, Genvoya, and other integrase-inhibitor-based combinations. Apretude competes with generic and branded oral tenofovir/emtricitabine PrEP, including Truvada and Descovy.
The injectable products do not compete only on efficacy. They compete on adherence, privacy, dosing frequency, clinic capacity, drug-acquisition cost, cold-chain requirements, and the risk of missed injections.
What is the financial trajectory for Cabenuva and Apretude?
Cabotegravir revenue has grown rapidly since the first FDA approvals in 2021. ViiV’s reporting does not isolate cabotegravir sodium or combine all cabotegravir-related sales into one audited line. Cabenuva and Apretude are disclosed as individual brands or within product-level HIV sales, while GSK reports ViiV’s overall HIV revenue.
The financial trajectory has four phases:
| Period |
Commercial stage |
Financial implication |
| 2021 |
FDA approval of Cabenuva and Apretude |
Initial launch costs, limited clinic penetration |
| 2022 |
Early U.S. adoption |
Revenue growth from treatment switching and PrEP launch |
| 2023 |
Broader reimbursement and clinic uptake |
Cabenuva became a material growth driver for ViiV |
| 2024 onward |
Portfolio expansion and international rollout |
Growth depends on injection capacity, reimbursement, and prevention procurement |
GSK has identified long-acting medicines, especially Cabenuva, as a major growth area within ViiV. Public disclosures show strong year-over-year growth from a relatively small base, but they do not provide a standalone cabotegravir-sodium income statement or product-level profitability measure.[4-6]
Cabenuva revenue drivers
Cabenuva has the stronger near-term commercial profile because it addresses an existing treated population. Revenue is supported by:
- Conversion of virologically suppressed patients from oral therapy.
- Monthly and two-month dosing options.
- Use in patients with adherence challenges.
- Specialty-pharmacy and clinic-administered reimbursement.
- The clinical value of reducing daily pill burden.
The main constraint is operational. Cabenuva requires healthcare-provider administration, patient scheduling, injection training, and inventory management. Those requirements increase gross-to-net complexity and can slow adoption in primary-care settings.
Apretude revenue drivers
Apretude has a larger theoretical prevention population but a more difficult market-access model. It competes with low-cost generic oral PrEP, which has a strong price advantage and does not require clinic-administered injections.
Apretude’s commercial advantages include:
- Two-month dosing.
- Reduced dependence on daily pill adherence.
- Potentially greater privacy for patients who do not want oral PrEP identified in the home.
- Public-health value in populations with poor persistence on daily therapy.
Its commercial disadvantages include injection-site reactions, the need for repeat clinic visits, HIV testing before each injection, and the risk of resistance if infection develops during delayed or missed dosing. The FDA requires HIV testing before initiation and before subsequent injections because cabotegravir’s long pharmacologic tail can create a period of subtherapeutic exposure.[2]
How does cabotegravir compare with competing HIV drugs?
| Attribute |
Cabenuva |
Apretude |
Daily oral PrEP or HIV therapy |
| Dosing |
Monthly or every two months |
Every two months |
Daily |
| Administration |
Healthcare provider |
Healthcare provider |
Self-administered |
| Primary market |
HIV treatment |
HIV prevention |
Treatment and prevention |
| Adherence proposition |
Removes daily dosing |
Removes daily dosing |
Familiar and widely available |
| Operational burden |
High |
High |
Low |
| Generic competition |
Limited near term |
Oral PrEP has generic competition |
Extensive in several categories |
| Key risk |
Missed injections and resistance |
Missed injections and resistance |
Daily adherence failure |
Cabotegravir has a stronger product-level barrier than many oral antiretrovirals because the commercial offering includes drug substance, injectable formulation, device-compatible packaging, administration procedures, and clinical monitoring.
What patents protect cabotegravir products?
Cabotegravir protection is likely to rely on several patent categories rather than a single compound patent:
- Core cabotegravir compound and chemical forms.
- Cabotegravir sodium compositions.
- Long-acting injectable nanosuspensions.
- Particle-size and crystallinity characteristics.
- Injectable formulations and excipient systems.
- Dosing schedules and treatment methods.
- HIV prevention methods involving periodic administration.
- Manufacturing processes for the injectable suspension.
- Combination treatment with rilpivirine.
The strongest commercial protections are likely to be formulation, manufacturing, and method-of-use claims tied to the long-acting injectable products. Compound protection is important, but the injectable product creates separate technical barriers because a generic applicant must reproduce a complex suspension with acceptable particle characteristics, sterility, injectability, stability, and pharmacokinetic performance.
The relevant patent holders and originators are ViiV Healthcare and affiliated entities. Cabenuva includes rilpivirine, which is associated with Janssen, creating a product-level intellectual-property structure involving more than one originator company.
What is the Orange Book status of cabotegravir products?
Apretude, Cabenuva, and Vocabria are FDA-approved prescription products. FDA Orange Book treatment is product-specific and depends on the patents submitted for each dosage form and indication.[7]
The principal regulatory distinction is between:
- A patent listed for the active ingredient;
- A patent listed for the injectable formulation;
- A patent covering a method of use;
- A patent covering a dosing regimen or treatment population.
Orange Book listing does not itself establish that every listed patent will survive litigation. It does create a basis for a generic applicant to file a Paragraph IV certification against listed patents.
When does cabotegravir lose exclusivity?
Cabotegravir does not have one universal loss-of-exclusivity date. The timing depends on the specific product, patent, regulatory exclusivity period, and litigation outcome.
The first FDA approvals occurred in January 2021 for Vocabria and Cabenuva and in December 2021 for Apretude. Five-year new chemical entity exclusivity, where applicable to the active moiety and regulatory approval, would place the earliest potential ANDA filing window around 2026, although patent barriers could extend the practical generic-entry date beyond that point.[1-3]
The commercial loss-of-exclusivity sequence is more likely to be gradual:
- Paragraph IV filings against Orange Book patents.
- ANDA litigation in federal district court.
- Possible settlement or licensed entry.
- Separate challenges to oral, injectable, formulation, and method patents.
- Later entry by products requiring specialized injectable manufacturing.
A generic oral cabotegravir product would not automatically substitute for Cabenuva or Apretude. The clinical and commercial value is concentrated in the long-acting formulations.
Which companies are challenging cabotegravir patents?
No broad, established generic challenge has produced a public market entry for Cabenuva or Apretude through the latest public disclosures considered here. The absence of a major commercial entrant does not eliminate future Paragraph IV risk. The likely challengers are large generic companies with sterile injectable manufacturing capabilities, complex-generic experience, and sufficient resources to litigate formulation patents.
Potential competitive pressure is greater for Vocabria tablets than for long-acting injectable cabotegravir. Oral cabotegravir sodium is technically simpler to manufacture, while the injectable products require more complex development and regulatory comparability work.
What generic entry risks exist?
Cabotegravir faces three distinct entry scenarios.
Oral cabotegravir entry
An oral generic could enter after applicable patents and exclusivity expire or after a successful challenge. Its market would be limited because Vocabria is generally used as an oral lead-in or bridging product rather than as a large standalone chronic therapy.
Long-acting cabotegravir entry
A generic or follow-on injectable would pose the largest revenue risk. Entry could reduce pricing for Cabenuva and Apretude, but substitution would depend on FDA approval, provider confidence, reimbursement rules, and supply reliability.
Authorized or licensed entry
ViiV could preserve value through a settlement or voluntary license that permits later entry under defined conditions. HIV medicines have historically used licensing and access arrangements in lower-income countries, but those agreements may not create immediate competition in the United States or other high-value markets.
What manufacturing and IP barriers protect cabotegravir?
The injectable product requires control over:
- Active-particle size and morphology.
- Suspension uniformity.
- Sterility and aseptic filling.
- Long-term physical stability.
- Injection force and needle compatibility.
- Dose reproducibility.
- Pharmacokinetic performance after intramuscular administration.
- Packaging, storage, and distribution.
These requirements raise development costs and lengthen generic approval timelines. A competitor may be able to challenge a patent but still require several years to establish commercial-scale sterile injectable production.
The long pharmacokinetic tail also creates clinical-development risk. A follow-on product must demonstrate reliable exposure over the full dosing interval and avoid subtherapeutic concentrations that could select for integrase resistance.
What licensing deals affect cabotegravir access?
ViiV has pursued access and licensing arrangements for HIV medicines through voluntary licensing and public-health partnerships. The most important commercial effect is geographic segmentation: low- and middle-income-country access programs can expand patient volume without directly setting U.S. or European pricing.
Cabotegravir’s prevention opportunity also depends on procurement agreements with governments, global health organizations, and public-health agencies. The World Health Organization has recommended long-acting injectable cabotegravir for HIV prevention in appropriate settings, supporting broader policy adoption.[8]
How strong is the cabotegravir patent estate?
The estate is commercially strong but legally layered. Its relative strengths are the injectable formulation, manufacturing know-how, dosing schedules, and regulatory complexity. Its weaknesses include the possibility that individual patents cover narrow formulation parameters, overlapping patent validity periods, or methods that may be difficult to enforce against products using different dosing or formulation approaches.
The practical protection period may exceed the earliest small-molecule exclusivity date because an entrant must clear several technical and regulatory barriers. That protection is more durable for Cabenuva and Apretude than for Vocabria tablets.
What is the outlook for cabotegravir revenue?
Cabotegravir should remain a major ViiV growth asset through the second half of the 2020s. The base case is continued Cabenuva growth, supported by treatment switching and broader provider adoption, with Apretude contributing a smaller but strategically important prevention franchise.
The main upside factors are wider reimbursement, improved clinic administration, public-health procurement, and use in populations with low adherence to daily oral therapy. The main downside factors are injection-site reactions, missed appointments, clinic capacity, reimbursement friction, generic oral PrEP pricing, and eventual patent challenges.
Key Takeaways
- Cabotegravir sodium underpins Vocabria, while cabotegravir injectable products are marketed as Cabenuva and Apretude.
- Cabenuva is the primary near-term revenue driver because it converts patients from existing HIV treatment regimens.
- Apretude has substantial prevention potential but faces stronger competition from inexpensive generic oral PrEP.
- ViiV does not separately report cabotegravir sodium revenue or standalone product profitability.
- The relevant IP estate includes compound, formulation, manufacturing, dosing, and method-of-use patents.
- Earliest regulatory exclusivity milestones begin around 2026, but practical generic entry may occur later because of injectable formulation and manufacturing barriers.
- No major commercial generic entry for Cabenuva or Apretude had been established in the public disclosures reviewed.
- The long-acting injectable platform creates higher switching costs and a stronger barrier than oral cabotegravir tablets.
FAQs
Is cabotegravir sodium the same as Cabenuva?
No. Cabotegravir sodium is the oral pharmaceutical form used in Vocabria tablets. Cabenuva is an injectable combination of cabotegravir and rilpivirine.
Is Apretude a PrEP drug or an HIV treatment?
Apretude is approved for HIV pre-exposure prophylaxis in people who do not have HIV but are at risk of sexually acquired infection. It is not approved as a complete treatment regimen for established HIV infection.
Can a generic cabotegravir tablet replace Cabenuva?
No. A generic tablet would not be therapeutically or commercially equivalent to the long-acting injectable regimen without separate FDA approval for the relevant formulation and use.
Why is Cabenuva harder to genericize than oral HIV medicines?
Cabenuva requires a sterile long-acting suspension with controlled particle characteristics, reproducible pharmacokinetics, reliable injection performance, and administration every one or two months.
What is the largest commercial risk to cabotegravir?
The largest risk is slower-than-expected injectable adoption caused by reimbursement restrictions, clinic capacity, missed appointments, injection-site reactions, and competition from effective low-cost daily oral regimens.
References
- U.S. Food and Drug Administration. (2021). Vocabria prescribing information.
- U.S. Food and Drug Administration. (2021). Apretude prescribing information.
- U.S. Food and Drug Administration. (2021). Cabenuva prescribing information.
- GSK plc. (2023). Annual report 2023.
- GSK plc. (2024). Full-year results 2024.
- ViiV Healthcare. (2024). Company product and pipeline information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- World Health Organization. (2022). Guidelines on long-acting injectable cabotegravir for HIV prevention.
